WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first three quarters ending September 30, 2026 (“Reporting Period”). The Company further raised its full-year guidance, citing strong performance across revenue, profit, and cash flow driven by the greater success of multiple customers’ products and its unique integrated CRDMO platform.
Financial Highlights
· Q1-Q3 2026 total revenue reached RMB 45.54 billion, up 38.6% year-on-year (YoY); revenue from Continuing Operations[2] up 46.3% YoY.
· Adjusted non-IFRS gross profit margin increased by 7.7 percentage points (pts) YoY to 54.8%.
· Adjusted non-IFRS net profit up 74.4% YoY to RMB 18.38 billion; adjusted non-IFRS net profit margin up 8.3pts YoY to 40.4%; adjusted non-IFRS diluted EPS up 68.8% YoY to RMB 6.21.
· Net profit per CAS[3] up 60.6% YoY to RMB 19.40 billion; diluted EPS up 55.6% YoY to RMB 6.55.
· Backlog for Continuing Operations up 36.4% YoY to RMB 76.74 billion as of September 30, 2026.
· Adjusted operating cash flow rose 58.9% YoY to RMB 17.28 billion.
Management Comment
Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, “Enabling our customers and benefiting patients is the cornerstone of WuXi AppTec’s sustained growth. Driven by the greater success of multiple customers’ products, the strength of our unique CRDMO business model, and the exceptional performance of our global team, we maintained broad-based momentum and delivered strong growth across revenue, profit, and cash flow in the first three quarters of 2026. Our backlog for Continuing Operations reached RMB 76.7 billion, and we have further raised our full-year guidance.”
“To efficiently meet our customers’ evolving needs, we are accelerating our global capacity development, enhancing our operational resilience, and driving high-quality growth, delivering even greater value for customers and shareholders alike.”
“We firmly believe that innovation begins with science and flourishes through execution. WuXi AppTec remains steadfast in ‘doing the right thing and doing it right.’ We will continue to enable global innovators and achieve our vision that ‘every drug can be made and every disease can be treated.’”
Shareholder Returns
The Company distributed a total of RMB 6.22 billion cash dividends in Q1-Q3, including RMB 4.71 billion[4] for the 2025 annual dividend, and RMB 1.51 billion for the 2026 interim dividend (representing a further increase from its first interim dividend of RMB 1.03 billion in 2025).
2026 Full-Year Outlook
Driven by the greater success of multiple customers’ products, our unique CRDMO model, and management and execution excellence, the Company has further raised its full-year guidance.
· 2026 total revenue target has been raised to RMB 61.0-61.9 billion (previously RMB 58.5-60.5 billion), with Continuing Operations revenue now expected to grow 40-42% YoY (previously 35-39%).
· The Company is confident in maintaining a stable and resilient adjusted non-IFRS net profit margin in 2026.
· 2026 capex forecast has been adjusted to RMB 8.0-8.5 billion (previously RMB 7.5-8.5 billion) to support accelerated global capacity development, including initiation of the new Changzhou site ahead of schedule.
· Along with business growth and efficiency improvements, 2026 adjusted free cash flow forecast has been raised to RMB 14.5-15.5 billion (previously RMB 13.5-14.5 billion).
